COVID-19 infection is linked to a roughly 50 percent increase in the risk of developing new-onset dementia, according to a systematic review and meta-analysis published in 2025. That elevated risk holds up even when researchers compare COVID patients to people who had other respiratory infections, though the picture gets murkier when the comparison group is limited to people who had influenza or sepsis. The connection between SARS-CoV-2 and lasting brain damage is not a single clean story but a tangle of vascular injury, persistent inflammation, immune misfires, and structural brain changes that researchers are still working to untangle.
How Much Does COVID Raise the Risk of Dementia?
The most comprehensive look at this question comes from a 2025 meta-analysis that pooled data from multiple large cohort studies. It found that people who had COVID-19 faced about a 49 percent higher hazard of being diagnosed with dementia compared to the general population. When the comparison was narrowed to people who had other respiratory tract infections but not COVID, the risk was still about 29 percent higher in the COVID group.1PubMed. Risk of new-onset dementia following COVID-19 infection: a systematic review and meta-analysis That distinction matters because it suggests the dementia risk is not simply a byproduct of being seriously ill with any lung infection. Something about COVID itself appears to carry additional risk for the brain.
Not every study, however, finds a dramatically elevated signal. One retrospective cohort study that compared COVID patients to people diagnosed with acute upper respiratory infections found that after a year, the rates of new dementia diagnoses were nearly identical, at about 1.8 percent in both groups.2PubMed. Incidence of Newly-Diagnosed Dementia After COVID-19 Infection versus Acute Upper Respiratory Infection: A Retrospective Cohort Study The follow-up period may have been too short, or the comparison group too similar, to capture the full effect. The meta-analysis, drawing on larger and longer datasets, carries more weight, but the mixed signals are a reminder that dementia typically takes years to develop, and the pandemic is still recent enough that the full picture has not emerged.
What the Cognitive Problems Actually Feel Like
When people talk about “brain fog” after COVID, they are describing something measurable. A systematic review of neurocognitive studies in long COVID found that every included study confirmed persistent cognitive changes, with the hardest-hit areas being executive function, memory, attention, and processing speed.3Archives of Clinical Neuropsychology. Neurocognitive Impairment in Long COVID: A Systematic Review In practical terms, that can mean struggling to plan a sequence of tasks, losing track of conversations, or feeling like your thinking has slowed down.
A study published in Brain found that nearly half of long COVID patients had measurable episodic memory deficits, and about a quarter showed impairment in overall cognitive function, including attention, working memory, processing speed, and verbal fluency.4PubMed. Brain and cognitive changes in patients with long COVID compared with infection-recovered control subjects These are not subtle differences detectable only in a lab. A quarter of patients in that study had cognitive scores low enough to be flagged as impaired. Language ability, interestingly, has not been studied as thoroughly, and the data available do not show the same consistent pattern of decline.
How COVID Damages the Brain
The mechanisms behind COVID-related brain damage are not a single pathway but several overlapping ones. Understanding which ones matter most is an active area of research, and the answer likely varies from person to person.
Blood-Brain Barrier Breakdown
One of the most consistent findings is that SARS-CoV-2 damages the blood-brain barrier, the tightly sealed layer of cells that normally keeps harmful substances in the bloodstream from reaching brain tissue. Autopsy studies of COVID patients have found clear signs of microvascular injury in the brain, including leakage of blood proteins like fibrinogen into the olfactory bulb and thinning of the vessel walls.5PubMed Central. Blood–brain barrier disruption and sustained systemic inflammation in individuals with long COVID-associated cognitive impairment Animal studies using mice engineered to be susceptible to the virus have confirmed the mechanism: the virus damages pericytes (cells that wrap around tiny blood vessels to stabilize them), destroys tight junctions between cells, and triggers vascular inflammation, all of which compromise the barrier.6PubMed Central. SARS-CoV-2 induces blood-brain barrier and choroid plexus barrier impairments and vascular inflammation in mice
Neuroinflammation and Immune Cell Activation
Even mild respiratory COVID infections can trigger significant neuroinflammation. Research has shown that microglia, the brain’s resident immune cells, become highly reactive after infection, and that this reactivity can impair the creation of new neurons in the hippocampus, deplete oligodendrocytes (cells responsible for insulating nerve fibers), and reduce myelinated axons.7PubMed Central. Role of Microglia, Decreased Neurogenesis and Oligodendrocyte Depletion in Long COVID-Mediated Brain Impairments The hippocampus is critical for memory, so damage there lines up with the memory complaints so common in long COVID.
Autopsy studies have confirmed this pattern. In one series of 17 COVID patients’ brains, researchers found three consistent patterns: widespread microglial activation throughout the brain, particularly in the cerebellar nuclei and white matter; pronounced activation of immune cells around blood vessels; and clusters of macrophages.8PubMed Central. Neuropathology in COVID-19 autopsies is defined by microglial activation and lesions of the white matter with emphasis in cerebellar and brain stem areas A larger autopsy series of 20 critically ill COVID patients found acute vascular damage in 80 percent of brains examined, along with moderate-to-severe microglial activation in 80 percent of cases. Notably, viral RNA was not detected in those brain samples, suggesting the brain injury was driven by the body’s inflammatory response rather than direct viral invasion.9PubMed Central. Brain autopsies of critically ill COVID-19 patients demonstrate heterogeneous profile of acute vascular injury, inflammation and age-linked chronic brain diseases
Autoimmune Attack on Brain Tissue
A particularly unsettling finding is that COVID appears to trigger the immune system to produce antibodies that target the brain itself. One study found anti-neuronal autoantibodies in 52 percent of post-COVID patients, targeting structures including myelin (the insulation around nerve fibers), specific types of neurons, and blood vessel walls. Patients who had these antibodies in their cerebrospinal fluid scored significantly worse on cognitive tests.10Brain, Behavior, and Immunity. Association of cerebrospinal fluid brain-binding autoantibodies with cognitive impairment in post-COVID-19 syndrome Separately, researchers found that long COVID is associated with elevated antibodies against multiple brain proteins, including myelin basic protein, synapsin, and tubulin. Antibodies against myelin basic protein turned out to be the strongest predictor of whether someone developed long COVID.11PubMed Central. Brain-targeted autoimmunity is strongly associated with Long COVID and its chronic fatigue syndrome as well as its affective symptoms
Structural and Functional Brain Changes on Imaging
The damage is not just biochemical; it shows up on brain scans. A longitudinal MRI study found that nearly two years after infection, post-COVID patients still showed widespread brain changes involving the brainstem, the motor cortex, and the limbic olfactory network. Fatigue had improved somewhat over those two years, but it persisted in most patients, and the brain changes were more pronounced in those who had been hospitalized.12PubMed Central. Two-year impact of COVID-19: Longitudinal MRI brain changes and neuropsychiatric trajectories
A two-year follow-up study using MRI found a mixed picture. Some areas of brain gray matter that had been reduced after infection, including parts of the frontal and temporal lobes, recovered to normal volumes by the two-year mark. But the cerebellum and vermis showed persistent reductions in gray matter that correlated with markers of inflammation.13Psychiatry Research. Two-year follow-up of brain structural changes in patients who recovered from COVID-19: A prospective study Recovery, in other words, coexists with ongoing injury in different parts of the brain.
Functional imaging tells a complementary story. PET scans of post-COVID patients with cognitive complaints show reduced metabolic activity in the frontal, temporal, and parietal lobes, with the largest areas of reduced activity in the frontal lobes. EEG recordings from the same patients show a pattern of slowed brain wave activity in matching regions, particularly increased slow-wave (delta and theta) activity and decreased fast-wave (alpha) activity in frontal and temporal areas.14Scientific Reports. Mapping brain changes in post-COVID-19 cognitive decline via FDG PET hypometabolism and EEG slowing There is a partial silver lining: the frontal hypometabolism seen in the acute phase of infection appears to fade over time, suggesting some degree of functional recovery in many patients.15PubMed. Persistent dysfunctions of brain metabolic connectivity in long-covid with cognitive symptoms
Blood Biomarkers of Brain Injury
You do not need a brain scan to detect COVID-related brain damage. Blood tests for neurofilament light chain (NfL), a protein released when nerve cells are injured, show significantly elevated levels in long COVID patients who report cognitive symptoms. Patients with both cognitive impairment and fatigue had the highest levels.16Molecular Psychiatry. Long COVID: plasma levels of neurofilament light chain in mild COVID-19 patients with neurocognitive symptoms A separate study found that among COVID-positive individuals, markers of neurodegeneration, blood-brain barrier dysfunction, and inflammation in the blood correlated with smaller brain volumes on MRI, especially in the hippocampus and limbic system. That correlation was not present in people who had not had COVID.17Alzheimer’s & Dementia. Elevated Blood Biomarkers of Neurodegeneration and Blood Brain Barrier Dysfunction Correlate with Lower MRI Regional Brain Volumes Two Years after COVID‐19 These biomarker findings are important because they may eventually give clinicians a way to identify who is at greatest risk for lasting cognitive decline without requiring expensive imaging.
The Alzheimer’s Connection
Some of the most concerning research links COVID infection to the specific molecular hallmarks of Alzheimer’s disease. A large study published in Nature Medicine found that SARS-CoV-2 infection was associated with a significant shift in the ratio of amyloid-beta 42 to amyloid-beta 40 in blood plasma. A drop in that ratio is an established marker of increased amyloid plaque buildup in the brain, the defining pathology of Alzheimer’s. The magnitude of the shift from COVID was comparable to about four years of normal aging or roughly half the effect of carrying one copy of the APOE-ε4 gene, the strongest known genetic risk factor for Alzheimer’s. Hospitalized patients showed over twice the shift seen in non-hospitalized cases.18Nature Medicine. Plasma proteomic evidence for increased β-amyloid pathology after SARS-CoV-2 infection
Laboratory work supports the biological plausibility of this connection. Researchers showed that the spike protein of SARS-CoV-2 can directly induce amyloid-beta protein aggregates in human retinal tissue, and that blocking a receptor called neuropilin-1 reduced this amyloid deposition.19PubMed Central. SARS-CoV-2 induces Alzheimer’s disease-related amyloid-β pathology in ex vivo human retinal explants and retinal organoids It is too early to say COVID causes Alzheimer’s, but the evidence suggests infection can accelerate the underlying molecular pathology, which is especially worrying for people who were already on a trajectory toward the disease.
Small Vessel Disease in the Brain
COVID also appears to damage the brain’s tiny blood vessels in a distinct way. A systematic review of cerebral small vessel disease in COVID patients found that microbleeds and ischemic lesions had a strong tendency to cluster in the corpus callosum and deep white matter, a pattern different from typical age-related small vessel disease.20Ageing Research Reviews. Cerebral small vessel disease pathology in COVID-19 patients: A systematic review Cerebral small vessel disease is already the leading cause of vascular cognitive impairment in older adults, and the concern is that COVID may independently contribute to this form of brain damage while also accelerating the age-related version. Research has suggested these microvascular changes can promote both white matter damage and amyloid pathology, potentially feeding into neurodegenerative processes.21PubMed Central. Cerebromicrovascular mechanisms contributing to long COVID: implications for neurocognitive health
The Brain’s Waste-Clearing System
A newer area of research focuses on the glymphatic system, the brain’s waste-clearing mechanism that operates primarily during sleep. Studies using specialized MRI techniques have found that recovered COVID patients, particularly those with sleep disturbances, show reduced glymphatic function. In one study, patients with right-sided glymphatic dysfunction were more likely to show cognitive decline on screening tests than those with left-sided dysfunction.22iScience. Glymphatic system dysfunction in recovered patients with mild COVID-19: A DTI-ALPS study The impairment was more pronounced in older patients, and a follow-up study found that glymphatic function partially recovered over two months as sleep improved.23PubMed Central. Glymphatic Function Alterations in Sleep Disorder Patients Post-COVID-19: A Longitudinal DTI-ALPS Study This matters because the glymphatic system is responsible for clearing amyloid-beta and other waste products from the brain. If COVID disrupts this system, it could compound the amyloid pathology described earlier.
Who Is Most Vulnerable
Severity of infection is one of the clearest risk factors for brain damage. Hospitalized patients consistently show more pronounced brain changes and greater shifts in Alzheimer’s biomarkers than those with mild cases. But mild infection is not benign for the brain either; the evidence for neuroinflammation, glymphatic disruption, and cognitive deficits extends to people who were never hospitalized.
Genetics play a role too. The APOE-ε4 allele, already the strongest common genetic risk factor for Alzheimer’s, also appears to influence COVID severity. One study found that the frequency of the ε4 allele was over four times higher in patients with severe COVID than in controls, and that carrying two copies of the allele was associated with a 17-fold increased risk of severe disease, even after excluding people with known APOE-related conditions like cardiovascular disease.24Scientific Reports. The association of APOE genotype with COVID-19 disease severity This creates a troubling double vulnerability: the same genetic variant that predisposes someone to Alzheimer’s also appears to predispose them to more severe COVID, which in turn causes more brain damage.
Age matters as well. Older COVID patients show more pronounced glymphatic impairment, greater vascular pathology, and were more likely to have pre-existing neurodegenerative or vascular changes in the brain that COVID could worsen. Autopsy studies found that chronic brain pathologies, including neurodegenerative diseases and vascular disease, were identified only in older patients.9PubMed Central. Brain autopsies of critically ill COVID-19 patients demonstrate heterogeneous profile of acute vascular injury, inflammation and age-linked chronic brain diseases
Recovery Over Time
The trajectory of cognitive recovery after COVID is not uniformly bleak, but it is uneven across different mental abilities. A longitudinal study tracking long COVID patients over 42 months found that learning and memory showed the most robust improvement, with verbal learning scores improving substantially from below-average to near-normal ranges by three years. Language fluency and processing speed also improved, though processing speed gains were delayed and did not become significant until after the two-year mark. Executive function improved modestly. However, attention, working memory, and memory retention remained essentially flat and did not show meaningful recovery over the entire follow-up period.25PubMed Central. Neurocognitive trajectories in long COVID: Evidence from longitudinal analyses
Meanwhile, psychiatric symptoms may worsen over time, particularly in people who were hospitalized. A UK study following hospitalized COVID patients found that depression scores increased from six months to two to three years post-infection, with both new cases emerging and existing symptoms worsening. Anxiety also increased. Fatigue initially improved from six to twelve months but then significantly deteriorated between twelve months and the two-to-three-year follow-up.26The Lancet Psychiatry. Neurological and cognitive sequelae 2–3 years after hospitalisation for COVID-19: a multicentre, prospective, longitudinal cohort study in the UK Depression and fatigue are themselves risk factors for cognitive decline, so this worsening psychiatric trajectory could compound the direct neurological damage.
Vaccination and Risk Reduction
Vaccination before infection appears to offer meaningful protection against cognitive problems. A meta-analysis of real-world studies found that vaccinated individuals had a 29 percent lower risk of developing long COVID compared to unvaccinated individuals. Among the specific symptoms reduced by vaccination, cognitive dysfunction was explicitly listed alongside kidney problems, muscle pain, and sleep disorders.27PubMed Central. Effect of COVID-19 Vaccines on Reducing the Risk of Long COVID in the Real World: A Systematic Review and Meta-Analysis The protection is not complete, and vaccinated people still develop long COVID and cognitive symptoms, but the reduction in risk is substantial enough to be one of the few clearly evidence-based preventive strategies available.
Treatment Options for Post-COVID Cognitive Impairment
Treatment for post-COVID cognitive decline is still largely based on rehabilitation strategies rather than targeted pharmacological therapies. Guidelines for primary care recommend non-pharmacological approaches including cognitive training (sometimes delivered through digital platforms), physiotherapy, and when appropriate, occupational or speech therapy.28PubMed Central. Management of cognitive impairment associated with post-COVID-19 syndrome: recommendations for primary care A systematic review of interventions for brain fog found that a combination of palmitoylethanolamide and luteolin (PEA-LUT), a supplement with anti-inflammatory properties, showed improvement in cognitive symptoms in two studies. Rehabilitation strategies also showed benefit for brain fog symptoms.29PubMed Central. Intervention modalities for brain fog caused by long-COVID: systematic review of the literature The evidence base is thin, and no treatment has been established in large randomized trials, but the research points toward addressing inflammation and supporting cognitive rehabilitation as the most promising directions.
Historical Parallels
The idea that a respiratory virus could trigger lasting brain disease is not new. The 1918 influenza pandemic was followed by a wave of encephalitis lethargica, a mysterious brain inflammation that caused parkinsonism and cognitive problems in survivors for decades afterward.30PubMed Central. SARS-CoV-2, aging, and Post-COVID-19 neurodegeneration The parallel has not been lost on researchers studying COVID’s neurological effects.31PubMed. Historical Perspectives on the Neurologic Manifestations of Viral Pandemics But with the exception of that pandemic, there is remarkably little data on the long-term neurological consequences of other major viral outbreaks in the past century. COVID may be the first pandemic where the tools exist to track brain changes in real time across millions of survivors, which means the neuroscience community is building a dataset that simply did not exist before. Whether the dementia risk from COVID stabilizes, climbs, or turns out to be primarily a concern for people who were already predisposed remains one of the most consequential open questions in neurology.